Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Talquetamab Regimens Boost Survival in Multiple Myeloma

2.

Enhanced CAR T cell therapy offers new strategy for lymphoma

3.

Hospital receives 300 backpacks designed to help kids get leukemia treatment on the go

4.

How Social Determinants of Health Are Linked to Outcomes in Multiple Myeloma

5.

Aspirin for CRC Risk Reduction May Benefit Unhealthy People Most


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot